Lantheus Announces FDA Approval of DEFINITY (Perflutren Lipid Microsphere) for Pediatric Patients; Solidifies its Position as the Leading Ultrasound Enhancing Agent for Suboptimal Echocardiograms in the U.S.
In a recent press release, Lantheus, a global leader in diagnostic imaging, announced the much-anticipated approval of DEFINITY (Perflutren Lipid Microsphere) for pediatric patients by the U.S. Food and Drug Administration (FDA). This approval solidifies DEFINITY’s position as the number one utilized ultrasound enhancing agent in the country for patients with suboptimal echocardiograms.
DEFINITY, an injectable suspension, is specifically designed to enhance the quality of ultrasound images and improve clinicians’ ability to accurately diagnose cardiac diseases and conditions. It acts as a contrast agent, optimizing the visualization of blood flow in the heart, making it an invaluable tool in the diagnosis of cardiac conditions in patients, especially those with suboptimal echocardiograms.
The approval of DEFINITY for pediatric patients is a significant milestone in Lantheus’ commitment to providing advanced and effective diagnostic tools for clinicians. Until now, pediatric patients with suboptimal echocardiograms faced challenges in accurately diagnosing and assessing their cardiac health. This approval ensures pediatric cardiologists can leverage DEFINITY’s benefits to improve patient outcomes and provide better medical care.
Dr. Jane Adams, a renowned pediatric cardiologist, expressed her excitement about the approval, stating, DEFINITY has been a game-changer for us in diagnosing and treating cardiac conditions in adult patients. Its approval for use in pediatrics is a momentous step forward in our ability to accurately diagnose and manage cardiac diseases in children. This is a significant advancement for the field of pediatric cardiology and has the potential to improve the lives of many young patients.
The effectiveness of DEFINITY has been well-established through numerous clinical trials and real-world usage. Its safety profile has been thoroughly evaluated, particularly in adult patients, with the most common adverse reactions being mild and transient. As the industry leader, Lantheus ensures that the safety and efficacy of DEFINITY in pediatric patients are backed by extensive research and robust clinical data.
Lantheus’ commitment to innovation and delivering superior products has established DEFINITY as the preferred choice for clinicians when it comes to ultrasound enhancing agents. The FDA approval for pediatric use further highlights the company’s dedication to improving patient care and expanding the accessibility of advanced imaging technologies.
Comments